Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pediatric trials require more safety measures, study finds
The UK research team that was led by Helen Sammons, a clinical associate professor in child health at the University of Nottingham’s Medical School, carried out a detailed
The UK research team that was led by Helen Sammons, a clinical associate professor in child health at the University of Nottingham’s Medical School, carried out a detailed
Sun Pharma’s product is being sold in the US by its marketing partner Caraco Pharmaceutical Laboratories. Sun Pharma had received a FDA approval for this earlier in March
The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received Crestor when compared to placebo.
Positive improvements were observed on several efficacy endpoints including tumour response rate and time to tumour progression. The primary efficacy variable was tumour response rate as assessed by
The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the US. It will assess the efficacy and tolerability of rufinamide in up
LY450139 is being tested to see if it can slow the progression associated with Alzheimer’s disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called
Teva will acquire Bentley, which at closing will consist solely of the generic pharmaceutical operations, for an aggregate cash purchase price of approximately $360 million. Shareholders of Bentley
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Genencor for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.
The growth was attributable to strong sales of the company’s inactivated hepatitis A vaccine, Healive, and ongoing marketing initiatives in support of the company’s seasonal influenza vaccine, Anflu.
The company plans to file a new drug application with the FDA within the next few months for its lead product candidate, bucindolol, for the treatment of chronic